The tweet was deleted by the author.
But we saved everything 🙂.
Stereotaxis, Inc. has received clearance from the U.S. Food and Drug Administration for its Synchrony robotic system.
This regulatory milestone supports the company’s efforts to advance robotic technology within catheterization laboratories. Synchrony aims to enhance the precision and safety of cardiac procedures as part of ongoing efforts to modernize the cath lab environment. Stereotaxis, Inc. issued a press release detailing the achievement and its significance for the future of interventional medicine.
Earlier this year, Stereotaxis introduced its latest robotic electrophysiology innovations at EHRA2026 in Paris. The company also launched a remote TeleRobotic Test Drive, allowing direct demonstrations of its RoboticEP technology. These initiatives reflect ongoing product development in the company’s robotics portfolio.